[Study of vaginal and intestinal microflora of women in the prenatal period and its correction in dysbacteriosis].
A comparative research of the structure of vaginal and intestinal microflora in norm and at kidney pathologies in women in the prenatal period was carried out. At physiologically normal course of pregnancy microbiocenosis of vagina and intestine does not contain pathogenic and conditional-pathogenic microorganisms. Lactic acid bacteria are fixed within the limits of 10(5)-10(8) CFU/1 ml in the vagina secretion and 10(7)-10(8) CFU/1 g in the intestine content. The spore microorganisms have completely disappeared in vaginal biocenosis of women with pyelonephritis after pharmacotherapy; and colibacterias has disappeared in 62% of women. Quantity of lactic acid bacteria has also decreased. Quantity of E. coli (10(8)- 10(9)) CFU/g, sporous microorganisms (10(3)-10(4)) CFU/g and yeast (10(4)-10(5)) CFU/g has considerably increased in the content of intestine. Lactic acid bacteria in content of the vagina are presented by: Lactobacillus acidophilus, L. plantarum, L. fermentum, L. vaginalis; in content of the intestine--L. plantarum and L. fermentum. All the isolated strains of lactobacilli are resistant to metrogyl and amphotericin, 87%--to cephoxitine, cypropfloxacine. Twenty three of 24 strains of lactic acid bacteria--antagonists of pathogenic microflora have shown adhesion to vaginal epthelium. The degree of adhesive activity depends on the strain and genus specificity of cultures. The highest index of adhesiveness in indicated in Enterococcus faecium (5.82 - 7.62) and Streptococcus salivarius subsp. thermophilus (2.74 - 6.40) strains. The screening of strains has been performed, which suppress growth of gas-producing microflora. The strain of Lactobacillus plantarum 200D proved to be the most active one. A complex of cultures of the lactic bacteria providing normalization of microbial cenosis of the vagina in women in the prenatal period has been selected as based on the data obtained. The biotechnology of production of vaginal suppositories is developed.
Podgorskiĭ
V S
VS
Liaskovskiĭ
T M
TM
Kovalenko
N K
NK
Oleshchenko
L T
LT
D000282:Administration, Intravaginal; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001422:Bacterial Adhesion; D005260:Female; D006801:Humans; D007422:Intestines / Q000382:microbiology*; D007778:Lactobacillus / Q000145:classification / Q000254:growth & development*; D011247:Pregnancy; D011295:Prenatal Care; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy; D014621:Vagina / Q000382:microbiology*
D000900:Anti-Bacterial Agents